Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action01:17

Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action

Nondepolarizing neuromuscular blockers induce paralysis by competitively blocking nicotinic acetylcholine receptors at the muscle end plate. Examples include pancuronium, mivacurium, vecuronium, and rocuronium. These quaternary ammonium derivatives are administered intravenously, are poorly absorbed, and are excreted via the kidneys.
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Depolarizing Blockers: Mechanism of Action01:28

Depolarizing Blockers: Mechanism of Action

Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

2025 Korean Guidelines for Cardiopulmonary Resuscitation: Part 10. Education and system implementation for enhanced chain of survival.

Clinical and experimental emergency medicine·2026
Same author

A multilevel longitudinal study of patient-physician communication in later life proactive health behaviors.

Patient education and counseling·2026
Same author

A chronic whole cigarette smoke extract model reveals redox-mitochondrial adaptation in human lung epithelial and organoid models.

Experimental & molecular medicine·2026
Same author

Tumor lysis syndrome in a pediatric patient with Burkitt lymphoma following emergence from general anesthesia: a case report.

Journal of medical case reports·2026
Same author

The Role of Interpersonal Communication Competence in Enhancing Intraoperative Hand-Off Quality.

AORN journal·2026
Same author

Updated pediatric cardiopulmonary resuscitation: a comprehensive review of the 2025 guidelines.

Anesthesia and pain medicine·2026

Related Experiment Video

Updated: May 16, 2026

Deep Neuromuscular Blockade Leads to a Larger Intraabdominal Volume During Laparoscopy
08:50

Deep Neuromuscular Blockade Leads to a Larger Intraabdominal Volume During Laparoscopy

Published on: June 25, 2013

Current recommendations for preventing residual neuromuscular blockade.

Jeong Eun Lee1, Hoon Jung1

  • 1Department of Anesthesiology and Pain Medicine, Kyungpook National University Hospital, School of Medicine, Kyungpook National University, Daegu, Korea.

Anesthesia and Pain Medicine
|May 14, 2026
PubMed
Summary

Postoperative residual neuromuscular blockade (rNMB) affects nearly 50% of patients despite current methods. Quantitative neuromuscular monitoring is now recommended to prevent rNMB and ensure patient safety during anesthesia recovery.

Keywords:
Airway extubationAnesthesia, generalNeuromuscular blockadeNeuromuscular blocking agentsNeuromuscular monitoringSugammadex

More Related Videos

Intra-Operative Neural Monitoring of Thyroid Surgery in a Porcine Model
08:16

Intra-Operative Neural Monitoring of Thyroid Surgery in a Porcine Model

Published on: February 11, 2019

Targeted Muscle Reinnervation: Surgical Protocol for a Randomized Controlled Trial in Postamputation Pain
03:26

Targeted Muscle Reinnervation: Surgical Protocol for a Randomized Controlled Trial in Postamputation Pain

Published on: March 8, 2024

Related Experiment Videos

Last Updated: May 16, 2026

Deep Neuromuscular Blockade Leads to a Larger Intraabdominal Volume During Laparoscopy
08:50

Deep Neuromuscular Blockade Leads to a Larger Intraabdominal Volume During Laparoscopy

Published on: June 25, 2013

Intra-Operative Neural Monitoring of Thyroid Surgery in a Porcine Model
08:16

Intra-Operative Neural Monitoring of Thyroid Surgery in a Porcine Model

Published on: February 11, 2019

Targeted Muscle Reinnervation: Surgical Protocol for a Randomized Controlled Trial in Postamputation Pain
03:26

Targeted Muscle Reinnervation: Surgical Protocol for a Randomized Controlled Trial in Postamputation Pain

Published on: March 8, 2024

Area of Science:

  • Anesthesiology
  • Critical Care Medicine
  • Pharmacology

Background:

  • Neuromuscular blocking agents (NMBAs) are vital in general anesthesia for surgical access and ventilation.
  • Postoperative residual neuromuscular blockade (rNMB) is a persistent challenge, with incidences near 50% even with advanced agents and reversal drugs.
  • Diagnosing rNMB is complicated in critically ill patients due to anesthetic effects.

Purpose of the Study:

  • To highlight the persistent challenge of postoperative residual neuromuscular blockade (rNMB).
  • To emphasize the shift towards quantitative neuromuscular monitoring (NMM) for NMBA management.
  • To underscore the importance of updated guidelines and education on NMM.

Main Methods:

  • Review of current challenges in managing NMBAs and preventing rNMB.
  • Discussion of the evolution from subjective clinical assessments to objective, quantitative NMM.
  • Incorporation of recent guidelines from major anesthesiology societies.

Main Results:

  • The incidence of rNMB remains high (around 50%) despite intermediate-acting NMBAs and sugammadex.
  • Quantitative NMM is increasingly recognized as crucial for accurate assessment of neuromuscular function.
  • Recent guidelines advocate for the appropriate use of NMBAs, reversal agents, and quantitative NMM.

Conclusions:

  • Preventing rNMB requires a paradigm shift towards objective, quantitative neuromuscular monitoring.
  • Updated guidelines recommend integrating quantitative NMM into standard practice when NMBAs are used.
  • Education on the proper use of quantitative NMM is essential for anesthesiologists to improve patient outcomes.